Amgen Reports Third Quarter 2018 Financial Results Read more about Amgen Reports Third Quarter 2018 Financial Results
Amgen Announces New FOURIER Analysis Showing Benefit With Repatha® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease Read more about Amgen Announces New FOURIER Analysis Showing Benefit With Repatha® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease
Amgen Announces Webcast Of 2018 Third Quarter Financial Results Read more about Amgen Announces Webcast Of 2018 Third Quarter Financial Results
Amgen Makes Repatha® (Evolocumab) Available In The US At A 60 Percent Reduced List Price Read more about Amgen Makes Repatha® (Evolocumab) Available In The US At A 60 Percent Reduced List Price
First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate Read more about First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate
Amgen Announces 2018 Fourth Quarter Dividend Read more about Amgen Announces 2018 Fourth Quarter Dividend
Amgen Invests £50 Million ($66 Million) In Oxford Nanopore Technologies Read more about Amgen Invests £50 Million ($66 Million) In Oxford Nanopore Technologies
Amgen Launches AMGEVITA™ (Biosimilar Adalimumab) In Markets Across Europe Read more about Amgen Launches AMGEVITA™ (Biosimilar Adalimumab) In Markets Across Europe
FDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma Read more about FDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia Read more about BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia
